Tirzepatide

What is Tirzepatide?

Tirzepatide is a novel “twincretin” — a single molecule that acts as an agonist at both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Developed by Eli Lilly, it represents the next generation of incretin-based therapy beyond first-generation GLP-1 agonists like semaglutide.

Marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, tirzepatide has shown superior efficacy to semaglutide in clinical trials.

How Tirzepatide Works

By activating two distinct hormone receptors, tirzepatide exerts complementary metabolic effects:

GLP-1 receptor activation:

• Stimulates insulin release
• Suppresses glucagon
• Slows gastric emptying
• Reduces appetite via brain receptors

GIP receptor activation:

• Further enhances insulin secretion
• May improve pancreatic beta cell function
• Complements GLP-1’s metabolic effects (exact mechanism still being studied)
• May modulate fat storage and adipogenesis

Clinical Evidence

Weight Loss — SURMOUNT Trials

The SURMOUNT-1 trial in adults with obesity showed:

• 22.5% average body weight reduction at the highest dose (15mg) over 72 weeks
• Nearly 63% of participants achieved ≥20% weight loss
• These results significantly exceed what was seen with semaglutide 2.4mg

Diabetes — SURPASS Trials

In the SURPASS-2 trial (direct comparison with semaglutide 1mg):

• Greater HbA1c reduction with tirzepatide at all doses
• More patients reached glycemic targets
• Comparable cardiovascular safety profile

Sleep Apnea

In 2024, the FDA approved Zepbound specifically for treating obstructive sleep apnea in adults with obesity — the first pharmacological treatment approved for this indication.

Side Effects

Similar to other GLP-1 agonists:

• Nausea, vomiting, diarrhea (most common)
• Constipation
• Decreased appetite
• Injection site reactions

Important Safety Information

• Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2 syndrome
• Increased pancreatitis risk (rare)
• Avoid in pregnancy

Medical Disclaimer: Tirzepatide is a prescription medication requiring medical supervision. This content is for educational purposes only. Consult your healthcare provider to determine if tirzepatide is appropriate for you.

Related Reading

• GLP-1 Agonists Explained: Semaglutide and Tirzepatide — GIP + GLP-1 dual agonism: how tirzepatide’s mechanism differs from semaglutide
• GLP-1 2026 Clinical Data: Tirzepatide vs. Semaglutide — SURMOUNT-5 head-to-head results, SURMOUNT-4 rebound data, and new safety signals
• GLP-1 and Muscle Loss: Preserving Lean Mass — Tirzepatide body composition data and strategies for preserving lean mass
• GLP-1 Patient Guide: What to Expect — Practical guide covering titration, side effect management, and realistic expectations
• GLP-1 Pharmacogenomics: Why Response Varies — Genetic and metabolic factors affecting tirzepatide response and weight loss outcomes